NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (âKSFâ) are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the me
Related Questions
What are the potential synergies and cost savings envisioned from combining BioSig with Streamex, and are they reflected in the current stock price?
What is the expected timeline for the investigation and its potential impact on the closing date of the merger?
What legal or regulatory liabilities could arise from the investigation that might impact shareholder value?
How might the investigation affect shortâterm liquidity and trading volume of BSGM?
Is there any insider trading activity or unusual options activity surrounding the announcement?
How does the merger valuation compare to recent transactions in the medical device/diagnostics sector?
How likely is the proposed merger to receive regulatory approval given the investigation by the former Attorney General and Kahn Swick & Foti?
How will the proposed 25% diluted ownership for current BioSig shareholders affect the valuation and earnings per share postâmerger?
What are the risks of the merger being delayed, renegotiated, or abandoned due to the investigation?
What are the specific terms and valuation metrics of the merger agreement (exchange ratio, cash consideration, any earnâouts or contingent payments)?